Assembling evidence grade
Loading
Independent evidence before payment.
Growth hormone secretagogue (GHRP)
Ipamorelin carries an Evidence Grade of B (Medium confidence). The strongest published evidence catalogued is human rct / review.
Grade B rule: One human RCT, Phase-2-only RCTs, or three or more other human studies.
The grade reflects the strength of the published evidence, not safety or efficacy. “Confidence” means how settled that grade is given the record — not how likely the compound is to work.
Human-use stop
This compound is investigational, warned or not approved for human use. A seller calling it “research only,” showing testimonials, registering a company or publishing a COA does not create an approved consumer medicine. Seller links below are market-surveillance records, not recommendations.
Ipamorelin is a selective growth-hormone secretagogue studied mainly in early-phase and animal pharmacology work.
Animal and in-vitro results are shown separately and must never be read as established human outcomes.
In plain terms: there are 2 randomised human trials here — the strongest kind of evidence. That is about the research, not about any particular seller or batch.
Strongest: randomised or pooled human trials.
Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International journal of colorectal disease, 2014.
Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical research, 1999.
Observational, open-label or small human studies.
none catalogued
Preclinical animal models — not a human outcome.
Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro. Histology and histopathology, 2002.
Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 1999.
Cell / tissue studies — not a human outcome.
none catalogued
Proposed mechanism — hypothesis, not evidence of effect.
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. Frontiers in aging, 2026.
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives. International journal of molecular sciences, 2026.
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports medicine (Auckland, N.Z.), 2026.
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. The American journal of sports medicine, 2026.
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews, 2026.
The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism. Physiology & behavior, 2024.
Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational andrology and urology, 2020.
Ipamorelin, the first selective growth hormone secretagogue. European journal of endocrinology, 1998.
On “cited by N”: citation counts (Crossref) reflect how often a paper has been referenced — a measure of academic attention, not of validity, safety, or whether a compound works. They do not affect the Evidence Grade, which is set purely by the strength of the evidence tier.
Human evidence is limited and early. No approved formulation. Animal pharmacology does not establish human benefit.
Not an approved medicine in major markets. Sold only as a “research chemical”, with no established safe consumer use, dose or supply standard.
PepCred flags any vendor selling this compound to the public as a consumer-protection concern. Status reflects regulator records; see the regulatory detail below.
Registered studies:
No FDA-approved (US) drug labelling found for this compound. A search of openFDA returned no approved product containing it as an active ingredient.
This reflects US FDA approval only — other regulators (e.g. MHRA, EMA) may differ; see the note below. Absence of an approved label is not, by itself, a safety finding, and a “research use only” label does not establish safety, legality or correct identity.
PepCred note: Not approved for human use.
These unranked records show where the name was detected. For an investigational, warned or unapproved compound, no seller, company registration, review score or COA creates an approved human-use route.
None of these is verified for human use.